share_log

The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More

The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More

生物技术未来一周(5月30日至6月4日):美国食品药品管理局关于伊顿合作癫痫药物的决定,ASCO会议正在进行等等
Benzinga Real-time News ·  2022/05/30 14:04
Biotech stocks advanced in the week ended May 27, tracking the overall positive sentiment of the broader market. Notwithstanding the week's strength, the sector has been one of the worst performers for the year-to-date period.
生物科技股在截至5月27日的一周内上涨,跟踪了大盘的整体积极情绪。尽管本周表现强劲,但该板块是今年迄今表现最差的板块之一。
Among notable developments, Genocea Biosciences, Inc. (NASDAQ:GNCA) announced that it is shuttering operations amid a cash crunch. The company also plans to voluntarily delist its shares from Nasdaq by June 2.
在值得注意的事态发展中,Genocea Biosciences,Inc.纳斯达克(Sequoia Capital:GNCA)宣布,在资金紧张的情况下,将停止运营。该公司还计划在6月2日前自愿将其股票从纳斯达克退市。
Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA) suffered a setback after its viral skin infection treatment candidate was rejected by the Food and Drug Administration on its third try.
Verrica制药公司。纳斯达克:VRCA)遭遇挫折,其首个病毒性皮肤感染治疗候选药物在第三次尝试时被美国食品和药物管理局拒绝。
Catalyst Biosciences, Inc. (NASDAQ:CBIO...
Catal...
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发